Verona Pharma Priced, Nasdaq: VRNA

Developing inhaled treatments for respiratory diseases.

Industry: Health Care

Latest Trade: $12.04 0.00 (0.0%)

First Day Return: 0.0%

Return from IPO: -10.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Our product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of PDE3 and PDE4, that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, potentially the first to act in both functions. We believe RPL554 has the potential to be the first novel class of bronchodilator in over 40 years. We have completed eight Phase 1 and 2a clinical trials for RPL554, with 282 subjects enrolled. In our clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo. Our clinical trials also have shown statistically significant improvements in lung function when RPL554 is added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 also has shown anti-inflammatory effects and has been well tolerated in our clinical trials, and has not been observed to result in the gastrointestinal or other side effects commonly associated with roflumilast, the only PDE4 inhibitor currently on the market for the treatment of chronic obstructive pulmonary disease (COPD). We are developing RPL554 for the treatment of patients with COPD and for the treatment of patients with cystic fibrosis (CF). We may also explore, alone or with a collaborator, development of RPL554 to treat asthma and other respiratory diseases.
more less
IPO News for Verona Pharma
more
IPO Data
IPO File Date 04/03/2017
Offer Price $13.50
Price Range $13.50 - $13.50
Offer Shares (mm) 5.9
Deal Size ($mm) $80
IPO Data
IPO Date 04/26/2017
Offer Price $13.50
Price Range $13.50 - $13.50
Offer Shares (mm) 5.9
Deal Size ($mm) $80
Underwriters
more
Company Data
Headquarters London, United Kingdom
Founded 2005
Employees 12
Website www.veronapharma.com